Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.53 |
| ▸ | SETD2 | Q9BYW2 | 3/20 | 0.53 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.53 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26097609 | 0.90 | NSD2 (0.55) | NSD2MEN1KMT2ARCE1SETD2 | |
| SCHEMBL25039644 | 0.90 | NSD2 (0.55) | NSD2MEN1KMT2ARCE1SETD2 | |
| SCHEMBL21378594 | 0.87 | ALB (0.53) | NSD2MEN1KMT2ARCE1PLA2G7 | |
| SCHEMBL17149696 | 0.87 | ALB (0.53) | NSD2MEN1KMT2ARCE1PLA2G7 | |
| SCHEMBL17149718 | 0.87 | ALB (0.53) | NSD2MEN1KMT2ARCE1PLA2G7 | |
| SCHEMBL24019706 | 0.85 | NSD2 (0.64) | NSD2SETD2SMYD3ALDH1A1HRH4 | |
| SCHEMBL25040208 | 0.85 | NSD2 (0.50) | NSD2MEN1KMT2ASETD2SMYD3 | |
| SCHEMBL26099736 | 0.84 | NSD2 (0.60) | NSD2SETD2SMYD3 | |
| SCHEMBL26095537 | 0.84 | NSD2 (0.60) | NSD2SETD2SMYD3HRH4 | |
| SCHEMBL26099135 | 0.84 | NSD2 (0.60) | NSD2SETD2SMYD3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. | 2024-09-12 | — | — | US | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | SETD2, CARM1, SETDB1 | NSD2 35/4885MEN1 3154/4885KMT2A 24/4885 |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | NSD2 14/4885MEN1 2641/4885KMT2A 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.